Modulation of Fas and FasL expression

Details Modulation of Fas and FasL expression Modulation of Fas and FasL expression

2002-10-25

2010-02-16

Angell, J. E. (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

07662792

ABSTRACT:
A method employing a composition comprising a 2 to 10 base synthetic oligonucleotide sequence selected from the group consisting of (GG)n, (GT)n, a(GT)nb, a(GA)nb, and a(GC)nb, wherein n is an integer between 1 and 3, and a and b are independently either none or one or more As, Cs, Gs, or Ts, or combinations thereof, for modulation of Fas and FasL expression or for modulation of the efficacy of therapeutic agents. The composition is administered to an animal or human with a pharmaceutically acceptable carrier, and optionally with a therapeutic agent, in an amount effective to modulate Fas and FasL expression, to treat the disease, or to modulate efficacy of the therapeutic agent.

REFERENCES:
patent: 4791101 (1988-12-01), Adolf
patent: 4983518 (1991-01-01), Schaffner et al.
patent: 5643890 (1997-07-01), Iversen et al.
patent: 6015710 (2000-01-01), Shay et al.
patent: 6150339 (2000-11-01), Rando et al.
patent: 6316190 (2001-11-01), Rein et al.
patent: 7125858 (2006-10-01), Filion et al.
patent: WO 94/08053 (1994-04-01), None
patent: WO 9417086 (1994-08-01), None
patent: WO 96/23508 (1996-08-01), None
patent: WO 97/20924 (1997-06-01), None
Ohyashiki, K. et al. Leukemia (1997) vol. 11, pp. 190-194.
Liu, X. et al. Expert Opinion on Therapeutic Patents (1996) vol. 6, pp. 457-470.
Coussens et al. (Nature 2002. vol. 420, pp. 860-867).
Griffith, et al., “Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege,” Science, Nov. 17, 1995, pp. 1189-1192, vol. 270.
Morassutti, et al., “Correlation between cytotoxic effect and binding to nuclear proteins of oligomeric d(GT)n sequences in human cancer CCRF-CEM cell line,” Minerva Biotec, Jun. 1995, pp. 176-181.
Filion, et al., “Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex,” Cancer Immunol Immunother (Mar. 2000) 49:325-334.
Morassutti, et al., “Effect of Oligomer Length and Base Substitutions On The Cytotoxic Activity and Specific Nucelar Protein Recognition of GTn Oligonucleotides in the Human Leukemic CCRF-CEM Cell Line,” Nucleosides and Nucleotides, 18(6&7), pp. 1711-1716(1999).
Reader, S., et al., “Identification of non-antisense phosphodiester oligonucleotides that induce cell cycle arrest and apoptosis in cancer cells,” Clinical Cancer Research (Nov. 2000), vol. 6, Supp., pp. 4571S.
Ballas et al., “Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA,” J. Immunol. Sep. 1, 1996, p. 1840-1845, vol. 157.
Bates et al., “Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding,” J. Biol. Chem., Sep. 10, 1999, p. 26369-26377, vol. 274.
Braun et al., “Cytotoxic T Cells Deficient in Both Functional Fas Ligand and Perforin Show Residual Cytolytic Activity yet Lose Their Capacity to Induce Lethal Acute Graft-Versus-Host Disease,” J. Exp. Med., 1996, p. 657-661, vol. 183.
Famularo et al., “Fas/Fas Ligand on the Road; An Apoptotic Pathway Common to AIDS, Autoimmunity, Lymphoproliferation and Transplantation,” Med. Hypoth., 1999, p. 50-62, vol. 53.
Hochhauser, D., Anti-Cancer Chemotherapeutic Agents, 1997, p. 903, vol. 8.
Klinman et al., “CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Interleukin 12, and Interferon y,” Proc. Natl. Acad. Sci. USA, Apr. 1996, p. 2879-2883, vol. 93.
Kondo et al., “Essential Roles of the Fas Ligand in the Development of Hepatitis,” Nature Med., Apr. 1997, p. 409-413. vol. 3, No. 4.
Lipford et al., “CpG-Containing Synthetic Oligonucleotides Promote B and Cytotoxic T Cell Responses to Protein Antigen: A New Class of Vaccine Adjuvants,” Eur. J. Immunol., 1997, p. 2340-2344, vol. 27.
Nagata, S., “Fas Ligand-Induced Apoptosis,” Ann. Rev. Genet., 1999, p. 29-55, vol. 33.
Nishioka et al., “An Augmentation of Fas (CD95/AP0-1) Antigen Induced by Radiation: Flow Cytometry Analysis of Lymphoma and Leukemia Cell Lines,” Int. J. Mol. Med., 1999, p. 275-278, vol. 3.
O'Connell, et al., “The Fas Counterattack: Fas-Mediated T Cell Killing by Colon Cancer Cells Expressing Fas Ligand,” J. Exp. Med., Sep. 1996, p. 1075-1082, vol. 184.
Owen-Schaub et al., “Fas and Fas Ligand Interactions in Malignant Disease (Review),” Int. J. Oncol., 2000, p. 5-12, vol. 17.
Sabelko-Downes et al., “The Role of Fas Ligand in vivo as a Cause and Regulator of Pathogenesis,” Curr. Opin. Immunol., Jun. 2000, p. 330-335, vol. 12.
Scaggiante et al., “Human Cancer Cell Lines Growth Inhibition by GTnOligodeoxyribonucleotides Recognizing Single-Stranded DNA-Binding Proteins,” Eur. J. Biochem., Mar. 1, 1998, p. 207-215, vol. 252.
Sheard et al., “Up-Regulation of Fas (CD95) in Human p534wud-typeCancer Cells Treated With Ionizing Radiation,” Int. J. Cancer, Nov. 27, 1997, p. 757-762, vol. 73.
Vlassov et al., “Transport of Oligonucleotides across Natural and Model Membranes,” Biochim. Biophys. Acta., 1994, p. 95-108, vol. 1197.
Wagner, R., “Gene Inhibition Using Antisense Oligodeoxynucleotides,” Nature, 1994, p. 333-335, vol. 372.
Wang et al., “Unmethylated CpG Motifs Protect Murine B Lymphocytes Against Fas-Mediated Apoptosis,” Cell Immunol., 1997, p. 162-167, vol. 180.
Wyllie et al., “Cell Death: The Significance of Apoptosis,” Int. Rev. Cytol., 1980, p. 251-306, vol. 68.
Wyllie A., “Glucocorticoid-Induced Thymocyte Apoptosis is Associated with Endogenous Endonuclease Activation,” Nature, 1980, p. 555-556, vol. 284.
Yoong et al., “Fas/Fas Ligand Interaction in Human Colorectal Hepatic Metastases,” Am. J. Pathol., Mar. 1999, p. 693-703, vol. 154.
Filion, M.C. et al., “Inhibition of cell cycle progression and induction of apoptosis in leukemia cells byMycobacterium phleiDNA and derived synthetic oligonucleotides.” Clinical Cancer Research (Nov. 7-10, 2000), vol. 6, Supp.; p. 4571S.
Filion, M.C., et al., “Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells.” British Journal of Cancer (Jan., 1999) 79(2) 229-35.
Promega Catalog 1993/94, Revolutions in Science, cover and pp. 90-91.

Affiliated with

Also associated with

Rating

Modulation of Fas and FasL expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulation of Fas and FasL expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of Fas and FasL expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4228636